文献速递淋巴瘤

IL10RA调节NPM1-ALK阳性间变性大细胞淋巴瘤对克唑替尼的敏感性

IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
PubMed 文献 · Blood · 2020-01-01

本研究通过全基因组CRISPR激活和敲除筛选及患者肿瘤RNA测序,发现IL10RA异常上调可通过重连STAT3信号通路绕过NPM1-ALK磷酸化,驱动ALCL对克唑替尼耐药;IL10RA表达与标准化疗反应不相关,提示克唑替尼联合化疗可能预防ALK抑制剂耐药特异性复发。

要点

  • 儿童NPM1-ALK阳性淋巴瘤临床试验中ALK抑制剂客观缓解率为54%至90%。
  • IL10RA上调通过重连STAT3信号通路绕过NPM1-ALK磷酸化驱动克唑替尼耐药。
  • IL10RA表达与儿童患者标准化疗反应不相关。

核心结论

  • ALCL对克唑替尼的耐药可由IL10RA异常上调驱动,其通过重连STAT3信号通路绕过NPM1-ALK的关键磷酸化。
  • IL10RA表达与儿童患者标准化疗反应不相关,提示克唑替尼联合化疗可能预防ALK抑制剂耐药特异性复发。

研究设计与样本

  • 研究在ALCL细胞系中进行全基因组CRISPR激活和敲除筛选,并结合ALK抑制剂复发患者肿瘤的RNA测序数据。

主要发现

  • 儿童NPM1-ALK融合蛋白驱动淋巴瘤的临床试验中,ALK抑制治疗的客观缓解率为54%至90%,但部分患者在治疗前3个月内进展。
  • IL10RA表达升高重连STAT3信号通路,绕过NPM1-ALK的关键磷酸化。
  • IL10RA表达与儿童患者标准化疗反应不相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven by nucleophosmin 1 (NPM1)-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54% to 90% in clinical trials; however, a subset of patients progressed within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is unknown. Through genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) activation and knockout screens in ALCL cell lines, combined with RNA sequencing data derived from ALK inhibitor-relapsed patient tumors, we show that resistance to ALK inhibition by crizotinib in ALCL can be driven by aberrant upregulation of interleukin 10 receptor subunit alpha (IL10RA). Elevated IL10RA expression rewires the STAT3 signaling pathway, bypassing otherwise critical phosphorylation by NPM1-ALK. IL-10RA expression does not correlate with response to standard chemotherapy in pediatric patients, suggesting that a combination of crizotinib and chemotherapy could prevent ALK inhibitor resistance-specific relapse.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Prokoph N, Probst NA, Lee LC, et al. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma. Blood. 2020. PMID: 32573700. doi:10.1182/blood.2019003793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。